Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 16Carcinoma, Renal Cell 14Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 7Carcinoma, Hepatocellular 7Neoplasms 6Carcinoma, Medullary 6Thyroid Neoplasms 5Melanoma 5Breast Neoplasms 5Ovarian Neoplasms 4Neuroendocrine Tumors 4Carcinoma, Transitional Cell 4Brain Neoplasms 4Thyroid Cancer, Papillary 3Small Cell Lung Carcinoma 3Sarcoma 3Pancreatic Neoplasms 3Lung Neoplasms 3Kidney Neoplasms 3Adenocarcinoma, Follicular 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Sarcoma, Ewing 2Recurrence 2Pheochromocytoma 2Paraganglioma 2Pain 2Osteosarcoma 2Multiple Myeloma 2

Interventions

trametinib 1tipifarnib 1pirfenidone 1peginterferon alfa-2b 1nilotinib 1mirdametinib 1dabrafenib 1cediranib 1cabozantinib 1binimetinib 1Vinblastine 1Surveys and Questionnaires 1Methotrexate 1Gadolinium DTPA 1Fluorodeoxyglucose F18 1Everolimus 1Acceptance and Commitment Therapy 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neurofibroma, Plexiform × cabozantinib × Clear all
NCT02101736 2023-05-24

NF105-CABO

University of Alabama at Birmingham

Phase 2 Completed
45 enrolled 10 charts
CNS

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡